

**THERMOGENESIS CORP. TO ANNOUNCE 2ND QUARTER  
FINANCIAL RESULTS ON FEBRUARY 9, 2005**

**RANCHO CORDOVA, Calif. – (February 7, 2005) –**

**THERMOGENESIS CORP. (Nasdaq: KOOL)**, a pioneer in designing and manufacturing medical devices, and designing sterile disposable bag sets to collect, concentrate, cryopreserve and archive therapeutic products such as stem cells from placental/umbilical cord blood (“PCB”), platelet gels, protein surgical sealants, and other related biological products sourced from single units of blood will report financial results for the quarter ending December 31, 2004, on Wednesday, February 9, 2005.

**Conference Call**

Management will host a conference call Wednesday, February 9, 2005 at approximately 11:00 AM (PST) to review the second quarter financial results. The call can be accessed by dialing **(800) 860-2442 within the U.S. or (412) 858-4600 outside the U.S.** and giving the conference name, “THERMOGENESIS”. Philip Coelho, Chairman & Chief Executive Officer, Kevin Simpson, President & Chief Operating Officer and Renee Ruecker, Chief Financial Officer will be on-line to discuss the second quarter results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately 5 minutes before the conference call begins.

**Replay**

A replay of the conference call will be available two hours after the call for the following five business days by dialing **(877) 344-7529 within the U.S. or (412) 317-0088 outside the U.S.** and entering the following account number: 459# and the following passcode: 364495.

**About ThermoGenesis Corp.**

After extensive research, ThermoGenesis Corp.’s newly introduced technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company's BioArchive® System as a critical enabling technology for cryogenic archiving of their samples of stem cells for transplant, while our CryoSeal® FS System is used to prepare hemostatic and adhesive surgical sealants from patient blood in about an hour. ThermoGenesis Corp. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

*The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.*

More Information, Contact:

Contact: THERMOGENESIS CORP.  
Renee M. Ruecker, CFO

[rruecker@thermogenesis.com](mailto:rruecker@thermogenesis.com)  
(916) 858-5100